Here's to CLSC and COR both rolling 1's on the binary dice for their rapidly approaching binary events.
Of the two, purely from a logic standpoint, I think COR has the lower hurdle - and COR is likely an easy double from 2.75 to 5.50 if the FDA removes the dosing limitation.
However CLSC should have more than a double in it if both its trials are a clear success.